|
Albright hereditary osteodystrophy (AHO), Pseudohypoparathyroidism (PHP)
|
GNAS 20q13.32
|
ME031-025R
|
€ 228
|
|
Albright hereditary osteodystrophy (AHO), Pseudohypoparathyroidism (PHP)
|
GNAS 20q13.32
|
ME031-050R
|
€ 456
|
|
Albright hereditary osteodystrophy (AHO), Pseudohypoparathyroidism (PHP)
|
GNAS 20q13.32
|
ME031-100R
|
€ 912
|
|
Beckwith-Wiedemann Syndrome (BWS), Russell-Silver Syndrome (RSS)
|
11p15 region, H19, IGF2, CDKN1C, KCNQ1
|
ME030-025R
|
€ 228
|
|
Beckwith-Wiedemann Syndrome (BWS), Russell-Silver Syndrome (RSS)
|
11p15 region, H19, IGF2, CDKN1C, KCNQ1
|
ME030-050R
|
€ 456
|
|
Beckwith-Wiedemann Syndrome (BWS), Russell-Silver Syndrome (RSS)
|
11p15 region, H19, IGF2, CDKN1C, KCNQ1
|
ME030-100R
|
€ 912
|
|
CpG Island Methylator Phenotype
|
|
ME042-025Rbasic research
|
€ 228
|
|
CpG Island Methylator Phenotype
|
|
ME042-050Rbasic research
|
€ 456
|
|
CpG Island Methylator Phenotype
|
|
ME042-100Rbasic research
|
€ 912
|
|
Fragile X
|
FMR1, AFF2
|
ME029-025R
|
€ 228
|
|
Fragile X
|
FMR1, AFF2
|
ME029-050R
|
€ 456
|
|
Fragile X
|
FMR1, AFF2
|
ME029-100R
|
€ 912
|
|
Lynch syndrome
|
MHL1, MSH2, CDKN2A, BRAF V600E
|
ME043-025Rbasic research
|
€ 228
|
|
Lynch syndrome
|
MHL1, MSH2, CDKN2A, BRAF V600E
|
ME043-050Rbasic research
|
€ 456
|
|
Lynch syndrome
|
MHL1, MSH2, CDKN2A, BRAF V600E
|
ME043-100Rbasic research
|
€ 912
|
|
Mismatch repair genes (MMR)
|
MLH1, MSH2, MSH6, MLH3, MSH3
|
ME011-025R
|
€ 228
|
|
Mismatch repair genes (MMR)
|
MLH1, MSH2, MSH6, MLH3, MSH3
|
ME011-050R
|
€ 456
|
|
Mismatch repair genes (MMR)
|
MLH1, MSH2, MSH6, MLH3, MSH3
|
ME011-100R
|
€ 912
|
|
Prader Willi syndrome (PWS), Angelman syndrome (AS)
|
PWS/AS region (15q11-13), MKRN3, MAGEL2, NDN, SNRPN, UBE3A, ATP10A, GABRB3, OCA2
|
ME028-025R
|
€ 228
|
|
Prader Willi syndrome (PWS), Angelman syndrome (AS)
|
PWS/AS region (15q11-13), MKRN3, MAGEL2, NDN, SNRPN, UBE3A, ATP10A, GABRB3, OCA2
|
ME028-050R
|
€ 456
|
|
Prader Willi syndrome (PWS), Angelman syndrome (AS)
|
PWS/AS region (15q11-13), MKRN3, MAGEL2, NDN, SNRPN, UBE3A, ATP10A, GABRB3, OCA2
|
ME028-100R
|
€ 912
|
|
Retinoblastoma (RB)
|
RB1 13q14
|
P047-025R
|
€ 228
|
|
Retinoblastoma (RB)
|
RB1 13q14
|
P047-050R
|
€ 456
|
|
Retinoblastoma (RB)
|
RB1 13q14
|
P047-100R
|
€ 912
|
|
Tumour suppressor genes
|
Various
|
ME001-025Rbasic research
|
€ 228
|
|
Tumour suppressor genes
|
Various
|
ME001-050Rbasic research
|
€ 456
|
|
Tumour suppressor genes
|
Various
|
ME001-100Rbasic research
|
€ 912
|
|
Tumour suppressor genes
|
Various
|
ME002-025Rbasic research
|
€ 228
|
|
Tumour suppressor genes
|
Various
|
ME002-050Rbasic research
|
€ 456
|
|
Tumour suppressor genes
|
Various
|
ME002-100Rbasic research
|
€ 912
|
|
Tumour suppressor genes
|
Various
|
ME003-025Rbasic research
|
€ 228
€ 159.60
|
|
Tumour suppressor genes
|
Various
|
ME003-050Rbasic research
|
€ 456
€ 319.20
|
|
Tumour suppressor genes
|
Various
|
ME003-100Rbasic research
|
€ 912
€ 638.40
|
|
Tumour suppressor genes
|
Various
|
ME004-025Rbasic research
|
€ 228
€ 159.60
|
|
Tumour suppressor genes
|
Various
|
ME004-050Rbasic research
|
€ 456
€ 319.20
|
|
Tumour suppressor genes
|
Various
|
ME004-100Rbasic research
|
€ 912
€ 638.40
|
|
Tumours, Cutaneous melanoma
|
9p21, CDKN2A, CDKNA2B
|
ME024-025R
|
€ 228
|
|
Tumours, Cutaneous melanoma
|
9p21, CDKN2A, CDKNA2B
|
ME024-050R
|
€ 456
|
|
Tumours, Cutaneous melanoma
|
9p21, CDKN2A, CDKNA2B
|
ME024-100R
|
€ 912
|